IRONWOOD PHARMACEUTICALS, INC. Increase (Decrease) in Other Current Liabilities
IRONWOOD PHARMACEUTICALS, INC. (IRWD) reported Increase (Decrease) in Other Current Liabilities of -$528.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherCurrentLiabilities · last filed 2026-08-06
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-06-30 was -$309.00K, a 108.42% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2026-03-31 was -$219.00K, a 217.11% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-12-31 was -$141.00K.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for the quarter ending 2025-09-30 was $249.00K, a 94.43% decline year-over-year.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2025 was $3.96M.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2024 was -$10.26M, a 2122.88% decline from fiscal 2023.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2023 was $507.00K, a 95.32% decline from fiscal 2022.
- IRONWOOD PHARMACEUTICALS, INC. increase (decrease) in other current liabilities for fiscal 2022 was $10.82M.
| Period end | Increase (Decrease) in Other Current Liabilities 3 month | Increase (Decrease) in Other Current Liabilities 6 month | Increase (Decrease) in Other Current Liabilities 9 month | Increase (Decrease) in Other Current Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$309.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$528.00K 10-Q · filed 2026-08-06 | -$669.00K derived: sum of 3 quarters · filed 2026-08-06 | -$420.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$219.00K 10-Q · filed 2026-05-07 | -$360.00K derived: sum of 2 quarters · filed 2026-05-07 | -$111.00K derived: sum of 3 quarters · filed 2026-05-07 | $3.56M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | -$141.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $108.00K derived: sum of 2 quarters · filed 2026-02-26 | $3.78M derived: sum of 3 quarters · filed 2026-08-06 | $3.96M 10-K · filed 2026-02-26 |
| 2025-09-30 | $249.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $3.92M derived: sum of 2 quarters · filed 2026-08-06 | $4.11M 10-Q · filed 2025-11-10 | -$17.57M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $3.67M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $3.86M 10-Q · filed 2026-08-06 | -$17.82M derived: sum of 3 quarters · filed 2026-08-06 | -$13.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $187.00K 10-Q · filed 2026-05-07 | -$21.49M derived: sum of 2 quarters · filed 2026-05-07 | -$17.02M derived: sum of 3 quarters · filed 2026-05-07 | -$11.24M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | -$21.67M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$17.20M derived: sum of 2 quarters · filed 2026-02-26 | -$11.43M derived: sum of 3 quarters · filed 2026-02-26 | -$10.26M 10-K · filed 2026-02-26 |
| 2024-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-10 | $10.25M derived: sum of 2 quarters · filed 2025-11-10 | $11.42M 10-Q · filed 2025-11-10 | $8.41M derived: sum of 4 quarters · filed 2025-11-10 |
| 2024-06-30 | $5.78M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | $6.95M 10-Q · filed 2025-08-11 | $3.94M derived: sum of 3 quarters · filed 2025-08-11 | $3.39M derived: sum of 4 quarters · filed 2025-08-11 |
| 2024-03-31 | $1.17M 10-Q · filed 2025-05-12 | -$1.84M derived: sum of 2 quarters · filed 2025-05-12 | -$2.39M derived: sum of 3 quarters · filed 2025-05-12 | $918.00K derived: sum of 4 quarters · filed 2025-05-12 |
| 2023-12-31 | -$3.01M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | -$3.56M derived: sum of 2 quarters · filed 2025-03-31 | -$251.00K derived: sum of 3 quarters · filed 2025-03-31 | $507.00K 10-K · filed 2025-03-31 |
| 2023-09-30 | -$554.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $2.75M derived: sum of 2 quarters · filed 2024-11-07 | $3.51M 10-Q · filed 2024-11-07 | $5.60M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-06-30 | $3.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $4.07M 10-Q · filed 2024-08-08 | $6.16M derived: sum of 3 quarters · filed 2025-03-31 | $8.89M derived: sum of 4 quarters · filed 2025-03-31 |
| 2023-03-31 | $758.00K 10-Q · filed 2024-05-09 | $2.85M derived: sum of 2 quarters · filed 2025-03-31 | $5.58M derived: sum of 3 quarters · filed 2025-03-31 | $7.97M derived: sum of 4 quarters · filed 2025-03-31 |
| 2022-12-31 | $2.09M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $4.83M derived: sum of 2 quarters · filed 2025-03-31 | $7.21M derived: sum of 3 quarters · filed 2025-03-31 | $10.82M 10-K · filed 2025-03-31 |
| 2022-09-30 | $2.74M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $5.12M derived: sum of 2 quarters · filed 2023-11-09 | $8.73M 10-Q · filed 2023-11-09 | $7.63M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-06-30 | $2.38M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-09 | $6.00M 10-Q · filed 2023-08-09 | $4.90M derived: sum of 3 quarters · filed 2024-02-16 | $5.01M derived: sum of 4 quarters · filed 2024-02-16 |
| 2022-03-31 | $3.62M 10-Q · filed 2023-05-04 | $2.52M derived: sum of 2 quarters · filed 2024-02-16 | $2.63M derived: sum of 3 quarters · filed 2024-02-16 | $2.48M derived: sum of 4 quarters · filed 2024-02-16 |
| 2021-12-31 | -$1.10M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-16 | -$990.00K derived: sum of 2 quarters · filed 2024-02-16 | -$1.14M derived: sum of 3 quarters · filed 2024-02-16 | -$1.27M 10-K · filed 2024-02-16 |
| 2021-09-30 | $111.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$36.00K derived: sum of 2 quarters · filed 2022-11-03 | -$169.00K 10-Q · filed 2022-11-03 | $1.08M derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-06-30 | -$147.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$280.00K 10-Q · filed 2022-08-04 | $967.00K derived: sum of 3 quarters · filed 2023-02-16 | $882.00K derived: sum of 4 quarters · filed 2023-02-16 |
| 2021-03-31 | -$133.00K 10-Q · filed 2022-05-05 | $1.11M derived: sum of 2 quarters · filed 2023-02-16 | $1.03M derived: sum of 3 quarters · filed 2023-02-16 | $925.00K derived: sum of 4 quarters · filed 2023-02-16 |
| 2020-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-16 | $1.16M derived: sum of 2 quarters · filed 2023-02-16 | $1.06M derived: sum of 3 quarters · filed 2023-02-16 | $1.03M 10-K · filed 2023-02-16 |
| 2020-09-30 | -$85.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$189.00K derived: sum of 2 quarters · filed 2021-11-04 | -$218.00K 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$104.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-05 | -$133.00K 10-Q · filed 2021-08-05 | ||
| 2020-03-31 | -$29.00K 10-Q · filed 2021-05-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |